Abstract
Valproic acid (VPA) has been reported to inhibit cancer cell growth and has therapeutic use in retinal diseases. However, the mechanism of this action remains unclear. In order to explore this mechanism, primary human retinal pigment epithelial (hRPE) cell cultures were established. Cell viability was assessed by the trypan blue exclusion method (T), and the cell proliferation was measured by 3H-thymidine incorporation (3H-thy). P38 synthesis was quantitated by using 14C-methionine-labeled P38 (14C-P38) by using P38-specific antibody. SB203580 (SB), a selective inhibitor of p38 MAPK, was also used to test the specificity of P38 stimulation. Antinuclear staining (NS) studies were performed by DAPI. Statistical significance was established by student's t-test. We observed that VPA (1mM) inhibited 10% fetal bovine serum (FBS)-stimulated cell proliferation (1.75±0.37 vs. 3.25±0.68 cells per 1μl±SEM, p<0.05, n=4). VPA also stimulated 14C-P38 synthesis in a dose-dependent manner. SB (30μM) inhibited VPA (4mM)-stimulated 14C-P38 synthesis (197.74±41.17 vs. 425.89±59.17, CPM±SEM, p<0.05, n=4) and increased hRPE cell proliferation (1.79±0.45 vs. 4.93±1.12 cells per 1μl±SEM, p<0.05, n=4); NS demonstrated VPA-induced cell damage. We conclude that VPA inhibits hRPE cell growth via P38 MAP mechanism and may be of therapeutic value in treating or preventing proliferative eye diseases.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call